{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:05:44Z","timestamp":1784196344009,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of the present study was to evaluate the performance and safety of high molecular weight (HMW) sodium hyaluronate (40\u00a0mg\/50\u00a0mL) for interstitial cystitis\/bladder pain syndrome (IC\/BPS) in real-world clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicenter European study was conducted in patients with the clinical diagnosis of IC\/BPS. Participants received weekly intravesical instillations for 12\u00a0weeks. The primary endpoint was responder rate at end of treatment\/week 12, defined as any improvement in IC\/BPS symptoms on the 7-point Patient Global Assessment (PGA) scale. Secondary endpoints included changes in bladder symptoms and quality of life assessed by visual analog scales (VAS), questionnaires, and voiding diaries at week 12 and 24.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Seventy-one (N\u2009=\u200974) patients enrolled were part of the full analysis set (mean [SD] age: 51.8 [16.9] years; 98.6% female) and 73\/74 patients were in the safety set (mean [SD] age: 51.9 [17.2] years; 98.6% female). Total responder rate was 90.1% (90% CI: 82.3, 95.3) at week 12 and 78.9% (90% CI: 69.4, 86.5) at week 24. Significant improvements from baseline were observed in VAS scores for urinary urgency and bladder pain at week 12 (\u201342.0; \u201339.3) and week 24 (\u201349.2; \u201349.2). Quality of life scores also improved significantly (+\u200917.1;\u2009+\u200927.2, all\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u2009.0001). Twenty patients (27.4%) reported 37 adverse events (AEs), including seven treatment-related AEs (incidents). No treatment-related serious AEs occurred and all incidents were resolved.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravesical HMW sodium hyaluronate improved IC\/BPS symptoms and quality of life through week 24 in most patients with a favorable safety profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11255-026-05035-1","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T17:57:58Z","timestamp":1770314278000},"page":"2963-2972","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A prospective, multicenter, real-world effectiveness and safety study of high molecular weight sodium hyaluronate for interstitial cystitis\/bladder pain syndrome"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3895-3574","authenticated-orcid":false,"given":"Robert","family":"Stoica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3626-8669","authenticated-orcid":false,"given":"Jose","family":"Medina-Polo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3437-744X","authenticated-orcid":false,"given":"Rustom P.","family":"Manecksha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2249-3459","authenticated-orcid":false,"given":"Christine","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Emmeluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2696-1358","authenticated-orcid":false,"given":"Hans Christian","family":"Kuhl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-363X","authenticated-orcid":false,"given":"Tarek","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5544-9540","authenticated-orcid":false,"given":"Claus R.","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"issue":"4","key":"5035_CR1","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/nau.20687","volume":"28","author":"P Hanno","year":"2009","unstructured":"Hanno P, Dmochowski R (2009) Status of international consensus on interstitial cystitis\/bladder pain syndrome\/painful bladder syndrome: 2008 snapshot. Neurourol Urodyn 28(4):274\u2013286","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"5035_CR2","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2007.09.019","volume":"53","author":"JP van de Merwe","year":"2008","unstructured":"van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK et al (2008) Diagnostic criteria, classification, and nomenclature for painful bladder syndrome\/interstitial cystitis: an ESSIC proposal. Eur Urol 53(1):60\u20137","journal-title":"Eur Urol"},{"issue":"6","key":"5035_CR3","first-page":"493","volume":"171","author":"JD Lilly","year":"1990","unstructured":"Lilly JD, Parsons CL (1990) Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet 171(6):493\u2013496","journal-title":"Surg Gynecol Obstet"},{"issue":"5","key":"5035_CR4","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0022-5347(17)32495-3","volume":"152","author":"RE Hurst","year":"1994","unstructured":"Hurst RE, Zebrowski R (1994) Identification of proteoglycans present at high density on bovine and human bladder luminal surface. The J Urol 152(5):1641\u20131645","journal-title":"The J Urol"},{"issue":"1","key":"5035_CR5","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/BF00182044","volume":"12","author":"RE Hurst","year":"1994","unstructured":"Hurst RE (1994) Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 12(1):3\u201310","journal-title":"World J Urol"},{"issue":"8","key":"5035_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00192-015-2890-7","volume":"27","author":"JM Barua","year":"2015","unstructured":"Barua JM, Arance I, Angulo JC, Riedl CR (2015) A systematic review and meta-analysis on the efficacy of intravesical therapy for bladder pain syndrome\/interstitial cystitis. Int Urogynecol J 27(8):1137\u20131147","journal-title":"Int Urogynecol J"},{"issue":"5","key":"5035_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0022-5347(05)67682-3","volume":"163","author":"DC Wei","year":"2000","unstructured":"Wei DC, Politano VA, Selzer MG, Lokeshwar VB (2000) The association of elevated urinary total to sulfated glycosaminoglycan ratio and high molecular mass hyaluronic acid with interstitial cystitis. J Urol 163(5):1577\u20131583","journal-title":"J Urol"},{"issue":"1","key":"5035_CR8","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/01.ju.0000161599.69942.2e","volume":"174","author":"VB Lokeshwar","year":"2005","unstructured":"Lokeshwar VB, Selzer MG, Cerwinka WH et al (2005) Urinary uronate and sulfated glycosaminoglycan levels: markers for interstitial cystitis severity. J Urol 174(1):344\u2013349. https:\/\/doi.org\/10.1097\/01.ju.0000161599.69942.2e","journal-title":"J Urol"},{"issue":"2","key":"5035_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0318277","volume":"20","author":"CJ van Ginkel","year":"2025","unstructured":"van Ginkel CJ, Baars CDM, Tiemessen DM, Jansen CFJ, Martens FMJ, Schalken JA, Janssen DAW (2025) Hyaluronic acid: function and location in the urothelial barrier for bladder pain syndrome\/interstitial cystitis, an in vitro study. PLoS ONE 20(2):e0318277. https:\/\/doi.org\/10.1371\/journal.pone.0318277","journal-title":"PLoS ONE"},{"issue":"1","key":"5035_CR10","first-page":"1","volume":"13","author":"S Poletajew","year":"2023","unstructured":"Poletajew S, Brz\u00f3zka MM, Krajewski W, Kamecki H, Nyk \u0141, Kryst P (2023) Glycosaminoglycan replacement therapy with intravesical instillations of combined hyaluronic acid and chondroitin sulfate in patients with recurrent cystitis, post-radiation cystitis and bladder pain syndrome: a narrative review. Pain Ther [Internet] 13(1):1\u201322","journal-title":"Pain Ther [Internet]"},{"key":"5035_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fimmu.2015.00201","volume":"6","author":"S Misra","year":"2015","unstructured":"Misra S, Hascall VC, Markwald RR, Ghatak S (2015) Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer. Front Immunol 6:6","journal-title":"Front Immunol"},{"issue":"10","key":"5035_CR12","doi-asserted-by":"publisher","first-page":"e26078","DOI":"10.1371\/journal.pone.0026078","volume":"6","author":"AS Maharjan","year":"2011","unstructured":"Maharjan AS, Pilling D, Gomer RH (2011) High and low molecular weight hyaluronic acid differentially regulate human fibrocyte differentiation. PLoS ONE 6(10):e26078","journal-title":"PLoS ONE"},{"issue":"12","key":"5035_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12121190","volume":"12","author":"F Plotti","year":"2024","unstructured":"Plotti F, Cundari GB, Ficarola F, Terranova C, De Cicco Nardone C, Montera R, Luvero D, Guzzo F, Silvagni A, Ferrari A, Caserta D, Angioli R (2024) Intravesical instillations of hyaluronic acid as first-line treatment in patients with interstitial cystitis\/bladder pain syndrome: use, efficacy and effects on quality of life. Healthcare 12(12):1190. https:\/\/doi.org\/10.3390\/healthcare12121190","journal-title":"Healthcare"},{"issue":"1","key":"5035_CR14","first-page":"26","volume":"59","author":"D Porru","year":"1997","unstructured":"Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM et al (1997) Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 59(1):26\u201329","journal-title":"Urol Int"},{"issue":"1","key":"5035_CR15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0022-5347(01)65933-0","volume":"156","author":"A Morales","year":"1996","unstructured":"Morales A, Emerson L, Nickel JC, Lundie M (1996) Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 156(1):45\u201348","journal-title":"J Urol"},{"issue":"2","key":"5035_CR16","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1080\/00365590410015876-1","volume":"39","author":"EB Kallestrup","year":"2005","unstructured":"Kallestrup EB, Jorgensen SS, Nordling J, Hald T (2005) Treatment of interstitial cystitis with Cystistat: a hyaluronic acid product. Scandinavian J Urol Nephrol [Internet] 39(2):143\u2013147","journal-title":"Scandinavian J Urol Nephrol [Internet]"},{"issue":"5","key":"5035_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00192-007-0515-5","volume":"19","author":"CR Riedl","year":"2007","unstructured":"Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pfl\u00fcger H (2007) Hyaluronan treatment of interstitial cystitis\/painful bladder syndrome. Int Urogynecol J 19(5):717\u2013721","journal-title":"Int Urogynecol J"},{"issue":"5","key":"5035_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1007\/s00192-007-0515-5","volume":"19","author":"CR Riedl","year":"2008","unstructured":"Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pfl\u00fcger H (2008) Hyaluronan treatment of interstitial cystitis\/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 19(5):717\u2013721. https:\/\/doi.org\/10.1007\/s00192-007-0515-5","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"5035_CR19","unstructured":"Interstitial Cystitis\/Bladder Pain Syndrome (IC\/BPS): Establishing drug development programs for treatment [Internet]. U.S. Food and Drug Administration. 2023. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/interstitial-cystitisbladder-pain-syndrome-establishing-drug-development-programs-treatment"},{"issue":"5","key":"5035_CR20","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1378\/chest.116.5.1208","volume":"116","author":"S Grant","year":"1999","unstructured":"Grant S, Aitchison T, Henderson E, Christie J, Zare S, Mc Murray J et al (1999) A comparison of the reproducibility and the sensitivity to change of visual analogue scales, Borg scales, and Likert scales in normal subjects during submaximal exercise. Chest 116(5):1208\u20131217","journal-title":"Chest"},{"key":"5035_CR21","doi-asserted-by":"crossref","unstructured":"Ioan Scarneciu, Bungau S, Lupu AM, Camelia Cornelia Scarneciu, Camelia Cristina Diaconu, Martha O, et al. (2019) Efficacy of instillation treatment with hyaluronic acid in relieving symptoms in patients with BPS\/IC and uncomplicated recurrent urinary tract infections - Long-term results of a multicenter study. 139:105067\u2013105077","DOI":"10.1016\/j.ejps.2019.105067"},{"issue":"4","key":"5035_CR22","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/JCMA.0000000000000498","volume":"84","author":"CP Tsai","year":"2021","unstructured":"Tsai CP, Yang JM, Liang SJ, Lin YH, Huang WC, Lin TY et al (2021) Factors associated with treatment outcomes after intravesical hyaluronic acid therapy in women with refractory interstitial cystitis: a prospective, multicenter study. J Chin Med Assoc 84(4):418\u2013422","journal-title":"J Chin Med Assoc"},{"issue":"3","key":"5035_CR23","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.tjog.2018.04.006","volume":"57","author":"CC Liang","year":"2018","unstructured":"Liang CC, Lin YH, Hsieh WC, Huang L (2018) Urinary and psychological outcomes in women with interstitial cystitis\/bladder pain syndrome following hyaluronic acid treatment. Taiwan J Obstet Gynecol 57(3):360\u2013363","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"2","key":"5035_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/j.1442-2042.2012.03135.x","volume":"20","author":"MC Lai","year":"2012","unstructured":"Lai MC, Kuo YC, Kuo HC (2012) Intravesical hyaluronic acid for interstitial cystitis\/painful bladder syndrome: a comparative randomized assessment of different regimens. Int J Urol 20(2):203\u2013207","journal-title":"Int J Urol"},{"issue":"9","key":"5035_CR25","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1111\/jsm.12507","volume":"11","author":"MJ Hung","year":"2014","unstructured":"Hung MJ, Su TH, Lin YH, Huang WC, Lin TY, Hsu CS et al (2014) Changes in sexual function of women with refractory interstitial cystitis\/bladder pain syndrome after intravesical therapy with a hyaluronic acid solution. J Sex Med 11(9):2256\u20132263","journal-title":"J Sex Med"},{"issue":"2","key":"5035_CR26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5152\/tud.2018.35920","volume":"45","author":"E Akbay","year":"2019","unstructured":"Akbay E, Cayan S, Kilinc C, Bozlu M, Tek M, Efesoy O (2019) The short-term efficacy of intravesical instillation of hyaluronic acid treatment for bladder pain syndrome\/interstitial cystitis. T\u00fcrk \u00dcroloji Dergisi\/Turkish J Urol 45(2):129\u2013134","journal-title":"T\u00fcrk \u00dcroloji Dergisi\/Turkish J Urol"},{"issue":"3","key":"5035_CR27","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1097\/01.ju.0000081163.46167.82","volume":"170","author":"LK Daha","year":"2003","unstructured":"Daha LK, Riedl CR, Hohlbrugger G, Knoll M, Engelhardt PF, Pfl\u00fcger H (2003) Comparative assessment of maximal bladder capacity 0.9% NaCl Versus 0 2 M Kcl. for the diagnosis of interstitial cystitis: a prospective controlled study. The J Urol 170(3):807\u2013809","journal-title":"The J Urol"},{"issue":"1","key":"5035_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0090-4295(02)01613-8","volume":"60","author":"M Leppilahti","year":"2002","unstructured":"Leppilahti M, Hellstr\u00f6m P, Tammela TLJ (2002) Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology. 60(1):46\u201351","journal-title":"Urology."},{"key":"5035_CR29","doi-asserted-by":"crossref","unstructured":"Gupta SK, Pidcock L, Parr N (2005) The potassium sensitivity test: a predictor of treatment response in interstitial cystitis. 96(7):1063\u20136","DOI":"10.1111\/j.1464-410X.2005.05776.x"},{"issue":"19","key":"5035_CR30","doi-asserted-by":"publisher","first-page":"5659","DOI":"10.3390\/jcm11195659","volume":"11","author":"P Abreu-Mendes","year":"2022","unstructured":"Abreu-Mendes P, Ara\u00fajo-Silva B, Charrua A, Cruz F, Pinto R (2022) Silodosin improves pain and urinary frequency in bladder pain syndrome\/interstitial cystitis patients. J Clin Med 11(19):5659\u20135669","journal-title":"J Clin Med"},{"issue":"S1","key":"5035_CR31","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/iju.13969","volume":"26","author":"Y Akiyama","year":"2019","unstructured":"Akiyama Y, Hanno P (2019) Phenotyping of interstitial cystitis\/bladder pain syndrome. Int J Urol 26(S1):17\u201319","journal-title":"Int J Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05035-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05035-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05035-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T09:19:05Z","timestamp":1784193545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05035-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["5035"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05035-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8336398\/v1","asserted-by":"object"}]},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MEDA Pharma GmbH & Co. KG (A Viatris Company) sponsored this study. CRR received consulting fees from MEDA Pharma GmbH & Co. KG (a Viatris company) and holds a fiduciary role in ESSIC. JMP, RPM, and RS report no conflicts. CK, ME, and HCK are employees of MEDA Pharma, a subsidiary of Viatris Inc., Canonsburg, USA; TK is employed directly by Viatris Inc.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by local research ethics committees at all participating sites and countries and adhered to the Declaration of Helsinki and the DIN ISO 14155 standard for clinical investigations of medical devices. All patients were required to provide written informed consent before study entry, and study participation was voluntary.","order":2,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}